Stockscreener 앱 받기
2.24
18.52%
0.35
전일 마감가:
$1.89
열려 있는:
$1.91
하루 거래량:
6.86M
Relative Volume:
1.71
시가총액:
$347.47M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-2.0935
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
+88.24%
1개월 성능:
+44.52%
6개월 성능:
-53.67%
1년 성능:
-65.11%
1일 변동 폭
$1.7903
$2.26
1주일 범위
$1.21
$2.26
52주 변동 폭
$1.15
$9.97
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
2.24 | 184.59M | 0 | -110.78M | -75.59M | -1.07 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN
Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus
Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus
Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa
Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus
Humacyte, Inc.: Spare Parts for People - Outsider Club
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com
Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus
Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus
Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - Insider Monkey
Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks
Durham firm with battered stock cuts jobs to save cash - The Business Journals
Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria
Humacyte, Inc. SEC 10-Q Report - TradingView
Positive Momentum and Financial Stability Drive Buy Recommendation for Humacyte - TipRanks
Humacyte (HUMA) Receives Continued 'Buy' Rating from Analyst | - GuruFocus
Transcript : Humacyte, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Humacyte (HUMA) Anticipates Q1 Earnings Announcement - GuruFocus
Humacyte, Inc. Reports First Quarter 2025 Financial Results and Market Launch of Symvess™ for Vascular Trauma Treatment - Nasdaq
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update - TradingView
Humacyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Humacyte Q1 2025 Earnings Call Transcript - MarketBeat
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc. (HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
HUMA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HUMA Shareholders Have Opportunity to Lead Humacyte, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Investors in Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 - The Manila Times
Humacyte, Inc. to Release First Quarter 2025 Financial Results on May 13, 2025 - Nasdaq
Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA ViolationsHagens Berman - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationHUMA - ACCESS Newswire
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - MSN
Humacyte Insiders Placed Bullish Bets Worth US$949.4k - Yahoo Finance
All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy - Yahoo Finance
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Humacyte Inc 주식 (HUMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sander Dale A. | CFO and Chief Corp. Deve. Off. |
Apr 10 '25 |
Buy |
1.53 |
20,000 |
30,600 |
40,600 |
| Parikh Shamik J | Chief Medical Officer |
Apr 10 '25 |
Buy |
1.55 |
7,500 |
11,625 |
7,500 |
| Sebelius Kathleen | Director |
Apr 08 '25 |
Buy |
1.32 |
50,000 |
66,000 |
91,207 |
| Green Charles Bruce | Director |
Apr 08 '25 |
Buy |
1.29 |
6,000 |
7,740 |
8,400 |
| Constantino Michael T. | Director |
Apr 07 '25 |
Buy |
1.26 |
16,000 |
20,160 |
32,950 |
| Constantino Michael T. | Director |
Dec 04 '24 |
Buy |
4.39 |
4,600 |
20,181 |
16,950 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Dougan Brady W | Director |
Nov 19 '24 |
Buy |
4.44 |
1,797 |
7,979 |
243,851 |
| Niklason Laura E | President, CEO and Director |
Nov 18 '24 |
Sale |
4.44 |
811,172 |
3,601,604 |
2,419,712 |
| Niklason Laura E | President, CEO and Director |
Nov 19 '24 |
Sale |
4.34 |
427,459 |
1,855,172 |
1,992,253 |
1.54%
7.58%
자본화:
|
볼륨(24시간):